Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Incyte Corporation
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
University Hospital, Essen
Memorial Sloan Kettering Cancer Center
Vincerx Pharma, Inc.
TuHURA Biosciences, Inc.
Mayo Clinic
Arcus Biosciences, Inc.
4SC AG
University of Birmingham
Ohio State University Comprehensive Cancer Center
EMD Serono
Immunomic Therapeutics, Inc.
National Cancer Institute (NCI)
OncoSec Medical Incorporated
Fate Therapeutics
Insel Gruppe AG, University Hospital Bern
Ludwig Institute for Cancer Research
Trans Tasman Radiation Oncology Group
University of California, Irvine
Incyte Corporation
AbbVie
AbbVie
University of Zurich
Incyte Corporation
Dana-Farber Cancer Institute
Novartis
Incyte Corporation
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
University Hospital, Grenoble
National Cancer Institute (NCI)
University of Southern California
Emory University
ImmunoGen, Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
Medical University of Graz